TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17986361
Drug: Clinical pathway
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical pathway (appropriate use of practice guidelines, supplies of drugs and ancillary services, new organization and procedures, patient education)
Study: 17701882
Drug: Cerivastatin 0.4
Normalized name: cerivastatin 0.4 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerivastatin 0.4 mg daily for 12 weeks
Study: 11354394
Drug: Dorzolamide 2%
Normalized name: Brimonidine Tartrate 0.1%, Dorzolamide 2% Ophthalmic drops, solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dorzolamide 2% 3 times daily
Study: 7955995
Drug: CS-045 (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: CS-045 (400 mg daily)
Study: 20854930
Drug: Sertraline+tDCS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline+tDCS
Study: 17212098
Drug: Weekly hepatic
Normalized name: hepatitis nosodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly hepatic arterial infusion (HAI) chemotherapy with 5-FU (1500 mg) for 8 weeks
Study: 17212098
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion group with identical total dosage of 5-FU
Study: 17212098
Drug: Weekly HAI
Normalized name: cromolyn sodium Ophthalmic Solution [Hay-Crom Hay Fever]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly HAI chemotherapy
Study: 17212098
Drug: HAI chemotherapy
Normalized name: cromolyn sodium Ophthalmic Solution [Hay-Crom Hay Fever]
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAI chemotherapy using a W spiral catheter
Study: 22260337
Drug: Nabilone (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nabilone (6 mg)
Study: 22260337
Drug: Nabilone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nabilone (4 mg), Nabilone (6 mg), Nabilone (8 mg)
Study: 10650898
Drug: Dolasetron plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolasetron plus dexamethasone (100 mg dolasetron i.v. + 20 mg dexamethasone)
Study: 10650898
Drug: Dolasetron alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolasetron alone (100 mg dolasetron i.v.)
Study: 27882007
Drug: Pemetrexed (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed (500 mg/m2 on d1) and Cisplatin (25 mg/m2 on d1-3)
Study: 27882007
Drug: Cisplatin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (25 mg/m2 on d1-3) and Fluorouracil (400 mg/m2)
Study: 18931202
Drug: Tranexamic Acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic Acid (TXA) - 10 mg/kg IV bolus after induction followed by 1 mg/kg/hr maintenance infusion
Study: 12185445
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (200 mg/ml)
Study: 8938880
Drug: Levocabastine nasal
Normalized name: levocabastine Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levocabastine nasal spray (0.5 mg/ml)
Study: 1769132
Drug: Fenfluramine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenfluramine (60 mg orally) + naloxone (3 mg/h infusion over 5 hours)
Study: 3987071
Drug: Fenfluramine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenfluramine (60 mg orally)
Study: 30196900
Drug: 0.8 g
Normalized name: Alcohol 0.8 g in 1 mL TOPICAL LIQUID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 g aspartame (placebo)
Study: 23516864
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of phospholipid nanoparticles
Study: 22851566
Drug: Paclitaxel 175
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 175 mg/m(2) every 3 weeks for four cycles (P3)
Study: 17655758
Drug: Guideline-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline-based treatment by occupational physicians (OPs)
Study: 25527036
Drug: 25 g
Normalized name: AndroGel 1.25 g Packets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 g glucose post-learning
Study: 23682073
Drug: 1 mg/day
Normalized name: Lyllana 0.1 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/day folic acid supplement
Study: 23682073
Drug: Control (treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (treatment without folic acid)
Study: 19159632
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (ascorbic acid) 3 g
Study: 17317022
Drug: Levothyroxine (L-T4)
Normalized name: L-T4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levothyroxine (L-T4) treatment after 7 weeks
Study: 15632894
Drug: Rosuvastatin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin therapy without compliance-enhancing program
Study: 9625576
Drug: Fludarabine, cytarabine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine, cytarabine, and G-CSF (FLAG)
Study: 7876398
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg sparfloxacin
Study: 7876398
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg sparfloxacin
Study: 7876398
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg sparfloxacin
Study: 3247592
Drug: Ranitidine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine administered at 1815 h
Study: 3247592
Drug: Ranitidine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine administered at 2200 h
Study: 30145306
Drug: Cognitive Working
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Working Memory Training (CWMT) with medication
Study: 18294251
Drug: Almotriptan (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almotriptan (12.5 mg) administered when pain intensity was mild (within 1 h of headache onset)
Study: 18294251
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered when pain intensity was moderate/severe
Study: 11514117
Drug: Kava extract
Normalized name: Kava extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kava extract with hormone replacement therapy
Study: 11514117
Drug: Hormone replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone replacement therapy (with and without progestogens)
Study: 9022538
Drug: OKG bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OKG bolus (10 g; n = 13)
Study: 9022538
Drug: Continuous gastric
Normalized name: gastric mucins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous gastric infusion of OKG (10, 20, or 30 g/d over 21 h; n = 13)
Study: 7528032
Drug: Ovarian ablation
Normalized name: modified Vaccinia Ankara-Bavarian Nordic Injection [Jynneos]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ovarian ablation (surgical or radiotherapeutic ablation, LH-RH agonists)
Study: 7528032
Drug: Ovarian ablation
Normalized name: modified Vaccinia Ankara-Bavarian Nordic Injection [Jynneos]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ovarian ablation (adjuvant therapy)
Study: 31756117
Drug: 30-μg ethinylestradiol/3-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30-μg ethinylestradiol/3-mg drospirenone (EE/DRSP)
Study: 31756117
Drug: 30-μg ethinylestradiol/2-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30-μg ethinylestradiol/2-mg chlormadinone acetate (EE/CMA)
Study: 28735202
Drug: Wii Fit™
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wii Fit™ exercise therapy
Study: 20429697
Drug: Combined potassium
Normalized name: Potassium
DrugBank: Potassium (DB14500)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined potassium and sodium channel blocking agent for conversion of atrial fibrillation
Study: 19281063
Drug: Biscuits (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biscuits (100 mg IF aglycones/two servings)
Study: 19281063
Drug: Cereal bars
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cereal bars (100 mg IF aglycones/two servings)
Study: 10190392
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid 400 microg + vitamin B12 500 microg + vitamin B6 12.5 mg
Study: 10190392
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid 1 mg + vitamin B12 500 microg + vitamin B6 12.5 mg
Study: 2310652
Drug: Dilevalol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dilevalol (200 mg or 400 mg)
Study: 17531571
Drug: Binodenoson 0.3,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Binodenoson 0.3, 0.5, or 1 microg/kg/min infusion
Study: 17531571
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of binodenoson
Study: 11336101
Drug: Fluvastatin extended-release
Normalized name: Fluvastatin Extended-Release Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin extended-release 80 mg
Study: 11336101
Drug: Fluvastatin extended-release
Normalized name: Fluvastatin Extended-Release Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin extended-release 160 mg
Study: 1273209
Drug: 0.2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/kg delta9-tetrahydrocannabinol (THC)
Study: 21849285
Drug: Delayed antiretroviral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed antiretroviral therapy
Study: 21849285
Drug: 6 months
Normalized name: leuprolide 45 mg/6 months intramuscular kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 months of abacavir-lamivudine-zidovudine concurrent with tuberculosis therapy
Study: 19437617
Drug: Topical phenylephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical phenylephrine 10% with intracameral lidocaine 1%
Study: 19437617
Drug: Topical cyclopentolate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cyclopentolate 1% and phenylephrine 10% with intracameral lidocaine 1%
Study: 17666348
Drug: Tangshenqing (TSQ)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tangshenqing (TSQ) combined with basic treatment
Study: 25384603
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no NAC treatment)
Study: 11144399
Drug: Cefdinir 7
Normalized name: Cefdinir
DrugBank: Cefdinir (DB00535)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefdinir 7 mg/kg b.i.d.
Study: 9131324
Drug: Amoxicillin/clavulanate 13.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/clavulanate 13.3 mg/kg t.i.d.
Study: 19775500
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg of cannabidiol (CBD)
Study: 19775500
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg Delta 9‐tetrahydrocannabinol (Delta 9‐THC)
Study: 18403122
Drug: Intrathecal fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intrathecal fentanyl (27.4 microg ED(50) in Group A, 12.8 microg ED(50) in Group G)
Study: 14967373
Drug: Metformin 500
Normalized name: metformin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 500 mg p.o. t.i.d. for 6 months
Study: 205382
Drug: Calcitriol (1,25(OH)2D3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitriol (1,25(OH)2D3) at a mean dose of 0.579 microgram/day for 3 months
Study: 21857969
Drug: Pharmaceutical intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical intervention in a randomized clinical trial of pharmaceutical care
Study: 9219204
Drug: Propranolol 80
Normalized name: propranolol 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 80 mg BID (combined beta 1, beta 2-antagonist)
Study: 7957426
Drug: IVGG therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVGG therapy
Study: 7957426
Drug: Low-dose PTX
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose PTX and IVGG combination therapy (10 mg/kg per day)
Study: 7957426
Drug: High-dose PTX
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose PTX and IVGG combination therapy (20 mg/kg per day)
Study: 25812826
Drug: Client-Centered Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Client-Centered Therapy (CCT)
Study: 12680791
Drug: Adjuvant whole
Normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant whole brain radiation therapy (WBRT) with focal treatment (stereotactic radiosurgery or conventional surgery)
Study: 12680791
Drug: Focal treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Focal treatment (stereotactic radiosurgery or conventional surgery)
Study: 8857326
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine (TNS)
Study: 26729760
Drug: IR dl‐MPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: IR dl‐MPH (0.3 mg/kg)
Study: 26729760
Drug: IR d‐MPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: IR d‐MPH (0.15 mg/kg)
Study: 22569045
Drug: Topical lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical lidocaine after Listerine mouthwash
Study: 7557866
Drug: UDCA/MTX (Ursodeoxycholic
Approvals — FDA: no, EMA: no, PMDA: no
Description: UDCA/MTX (Ursodeoxycholic acid 13 to 15 mg/kg/d and Methotrexate 0.25 mg/kg/wk)
Study: 388402
Drug: Tienilic acid
Normalized name: Tienilic acid
DrugBank: Tienilic acid (DB04831)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tienilic acid 250 mg once and twice daily
Study: 388402
Drug: Hydrochlorothiazide 50
Normalized name: hydrochlorothiazide 50 MG
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide 50 mg once and twice daily
Study: 31722679
Drug: Multimodal analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal analgesia with ropivacaine wound infiltration and intravenous flurbiprofen axetil
Study: 18042869
Drug: Injection-infusion with
Normalized name: Marcaine with Epinephrine Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection-infusion with levobupivacaine
Study: 18042869
Drug: Placebo injection-infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injection-infusion
Study: 10335995
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron (3 x 100 mg Fe2+ per day for 5 weeks before operation)
Study: 10335995
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron (200 mg Fe3+ after each donation with initial i.v. iron supplementation for hemoglobin under 15 g/dL)
Study: 10335995
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no iron medication)
Study: 8565027
Drug: BDP AQ
Approvals — FDA: no, EMA: no, PMDA: no
Description: BDP AQ Forte (0.084%) nasal spray 336 micrograms once daily
Study: 973959
Drug: Propranolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (100 mg)
Study: 25931216
Drug: Stopping immunosuppressive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stopping immunosuppressive agents (SD group)
Study: 25931216
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (did not stop immunosuppressive drugs)
Study: 8882471
Drug: Ranitidine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine and antacid (group 2)
Study: 8882471
Drug: H2-receptor antagonist
Normalized name: H2-receptor antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: H2-receptor antagonist and antacid (group 3, H. pylori-negative patients)
Study: 6669871
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment (rest in splints, non‐steroidal anti‐inflammatory drugs, gold or anti‐malaria agent) for 4-5 months
Study: 6669871
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (non-surgical treatment)
Study: 6669871
Drug: All patients
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patients (surgical and conservative treatment)
Study: 29405368
Drug: Proactive telephone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proactive telephone support (daily calls for up to 14 days after discharge)
Study: 12096707
Drug: Nurse-managed smoking
Normalized name: PAD,NURSING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nurse-managed smoking cessation program including physician advice, bedside education and counseling, take-home materials, nicotine replacement therapy, and post-discharge counseling calls.
Study: 26830468
Drug: DAS181 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAS181 (10 mg administered via dry particle inhaler on 3 consecutive days)
Study: 25332321
Drug: Fish-oil supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish-oil supplementation (1.5 g LC n-3 PUFAs/d)
Study: 22302719
Drug: Letrozole (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole (10 mg daily for 3 days)
Study: 1491396
Drug: oral Ca
Normalized name: coral calx
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral Ca (control)
Study: 30332482
Drug: Sufentanil 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil 1.5 μg/kg
Study: 30332482
Drug: Sufentanil 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil 2.0 μg/kg
Study: 30332482
Drug: Sufentanil 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil 2.5 μg/kg
Study: 27207411
Drug: DDS-1 strain
Normalized name: Haemagglutinin-strain B
DrugBank: Haemagglutinin-strain B (DB15482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DDS-1 strain of Lactobacillus acidophilus (1 dose daily for 4 weeks)
Study: 22331758
Drug: Bicalutamide 50-mg
Normalized name: bicalutamide 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicalutamide 50-mg tablets (test formulation)
Study: 20558755
Drug: L-NAME infusion
Normalized name: L-NAME
DrugBank: N-omega-nitro-L-arginine methyl ester (DB12750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NAME infusion
Study: 8536087
Drug: Daily use
Normalized name: ALCOHOL 75 mL in 100 mL TOPICAL GEL [Better For Daily Use EAAE Disinfectant]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily use of xylitol chewing gum (study group)
Study: 8536087
Drug: Daily use
Normalized name: ALCOHOL 75 mL in 100 mL TOPICAL GEL [Better For Daily Use EAAE Disinfectant]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily use of xylitol chewing gum (control group)
Study: 29906570
Drug: FOND-O (Fosaprepitant,
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOND-O (Fosaprepitant, Ondansetron, Dexamethasone + Olanzapine 10 mg)
Study: 25414047
Drug: PS+PA (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: PS+PA (300 mg PS + 240 mg PA/day)
Study: 27104905
Drug: mHealth accelerometer-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: mHealth accelerometer-based physical activity prescription
Study: 22162508
Drug: valproic acid
Normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: valproic acid (300 mg bid) with early or late addition of lacosamide (200 mg bid)
Study: 22162508
Drug: lacosamide (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: lacosamide (200 mg bid) with early or late addition of valproic acid (300 mg bid)
Study: 17346530
Drug: Antibiotics (metronidazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics (metronidazole plus azithromycin)
Study: 7942354
Drug: Mefloquine (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mefloquine (750 mg given immediately, followed by 500 mg 6 h later) with tetracycline (250 mg four times daily)
Study: 7942354
Drug: Quinine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinine (600 mg every 8 h for seven days) with tetracycline (250 mg four times daily)
Study: 31415392
Drug: Individualized occlusal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized occlusal splint therapy applied during day‐ and nighttime plus usual care (n=30)
Study: 24065294
Drug: Combination exercise
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination exercise training (aerobic, strength, and stretching exercise trainings) 3 days per week for 4 weeks (12 workouts total)
Study: 17928625
Drug: Candesartan (32
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan (32 mg daily)
Study: 17928625
Drug: Quinapril (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril (20 mg daily)
Study: 21239359
Drug: Abacavir 300
Normalized name: abacavir 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abacavir 300 mg twice daily
Study: 11901939
Drug: Diuretic and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretic and ACE inhibitor combination
Study: 9853849
Drug: Org 37462
Normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Org 37462 (ganirelix) 0.0625 mg
Study: 9853849
Drug: Org 37462
Normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Org 37462 (ganirelix) 0.125 mg
Study: 9853849
Drug: Org 37462
Normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Org 37462 (ganirelix) 0.25 mg
Study: 9853849
Drug: Org 37462
Normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Org 37462 (ganirelix) 2 mg
Study: 9853849
Drug: Org 37462
Normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Org 37462 (ganirelix) 1 mg
Study: 3354872
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg preservative-free morphine sulfate in 0.2 ml solution added to hyperbaric spinal bupivacaine
Study: 3354872
Drug: 0.2 ml
Normalized name: isopropyl alcohol 0.2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 ml saline added to bupivacaine (Control)
Study: 26415375
Drug: Levofloxacin (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin (750 mg once daily for 10 days)
Study: 24091269
Drug: Early removal
Normalized name: Super Spot Remover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early removal group (drainage < 300 ml/24 h), n = 41
Study: 24091269
Drug: Traditional management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional management group (drainage < 100 ml/24 h), n = 29
Study: 22044691
Drug: Docetaxel addition
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel addition to adjuvant anthracycline-based chemotherapy
Study: 19070056
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (20 mg day(‐1))